Safety and Efficacy of Percutaneous Mitral Valve-in-Valve and Mitral Valve-in-Ring Procedures: Systematic Review and Pooled Analysis of 30 Day and One Year Outcomes. Issue 5 (3rd September 2018)

• Record Type: Journal Article
• Authors: Sengodan, Prasanna; Sankaramangalam, Kesavan; Jobanputra, Yash; Athappan, Ganesh; Jaber, Wael; White, Jonathon; Mick, Stephanie; Navia, Jose; Krishnaswamy, Amar; Tuzcu, E. Murat; Kapadia, Samir
• Is Part Of: Structural heart. Volume 2:Issue 5(2018)
• Page Start: 421
• Page End: 430
• Publication Date: 2018-09-03
• Subjects: Mitral valve-in-valve -- mitral valve-in-ring -- 30-day outcomes -- 1-year outcomes; Heart -- Diseases -- Periodicals; Congenital heart disease -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular Diseases; Cardiovascular system -- Diseases; Congenital heart disease; Heart -- Diseases; Periodicals; 616.12
• DOI: 10.1080/24748706.2018.1497239
• Languages: English
• ISSNs: 2474-8706

Abstract

ABSTRACT: Background : The purpose of this study was to perform a systematic review and pooled analysis to evaluate 30-day and 1-year outcomes of transcatheter mitral valve-in-valve (VIV) and valve-in-ring (VIR) procedures. Data from the Valve-in-Valve Data Registry revealed that there were several safety and efficacy concerns, although procedural success was achieved in most cases. Methods : Studies reporting data on either mitral VIV and/or VIR with at least five patients were pooled using weighted proportional analysis. Results : The 30-day pooled estimate of all-cause mortality in the mitral VIV group was 7%, valve embolization, 5%, stroke, 3%, and major bleeding, 9%. At 1 year the all-cause mortality was 11%, valve thrombosis, 10%, stroke, 6%, and major bleeding, 16%. In the mitral VIR group, the 30-day pooled estimate for all-cause mortality was 8%, renal failure, 11%, valve embolization, 3%, and left ventricular outflow tract obstruction, 10% and at 1 year the all-cause mortality was about 22%. Conclusions : Mitral VIV and VIR procedures are safe and feasible in high risk surgical candidates. The long-term safety and efficacy data beyond 1 year for both mitral VIV and VIR need to be established.